Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,507 | -11,546 | -6,210 | -24,590 | -18,866 |
| Depreciation Amortization | 170 | 158 | 37 | 211 | 342 |
| Accounts receivable | 300 | 300 | 300 | -300 | N/A |
| Other Working Capital | 177 | 995 | 259 | 1,718 | 656 |
| Other Operating Activity | 3,683 | 1,194 | 853 | 8,433 | 6,898 |
| Operating Cash Flow | $-13,178 | $-8,898 | $-4,761 | $-14,528 | $-10,970 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -174 | -170 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $-174 | $-170 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 300 | N/A | N/A | N/A | N/A |
| Debt Repayment | -219 | -130 | -42 | -223 | -167 |
| Common Stock Issued | 1,060 | N/A | 0 | 17,647 | 7,214 |
| Financing Cash Flow | $1,141 | $-130 | $-42 | $17,424 | $7,047 |
| Beginning Cash Position | 13,100 | 13,100 | 13,100 | 10,378 | 10,378 |
| End Cash Position | 1,063 | 4,072 | 8,297 | 13,100 | 6,285 |
| Net Cash Flow | $-12,037 | $-9,028 | $-4,803 | $2,722 | $-4,093 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,178 | -8,898 | -4,761 | -14,528 | -10,970 |
| Capital Expenditure | N/A | N/A | N/A | -174 | -170 |
| Free Cash Flow | -13,178 | -8,898 | -4,761 | -14,702 | -11,140 |